Mbx Biosciences Inc stock is traded at $48.46, with a volume of 428,647. It is down -7.66% in the last 24 hours and down -17.22% over the past month. MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include canvuparatide (MBX 2109), imapextide (MBX 1416), and MBX 4291.
Previous Close:
$52.48
Open:
$52.63
24h Volume:
428,647
Relative Volume:
0.98
Market Cap:
$2.33B
Revenue:
-
Net Income/Loss:
-$86.97M
P/E Ratio:
-
EPS:
-$2.42
Net Cash Flow:
-$81.88M
1W Performance:
-11.15%
1M Performance:
-17.22%
6M Performance:
+63.72%
1Y Performance:
+114.90%
1-Day Range:
$47.55$52.69
1-Week Range:
$47.55$57.42
52-Week Range:
$20.34$72.64
Mbx Biosciences Inc Stock (MBX) Company Profile
Name
Mbx Biosciences IncSector
HealthcareIndustry
BiotechnologyPhone
(317) 989-3100Address
11711 N. MERIDIAN STREET, CARMEL, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS